Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis.

about

Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis.

Item

http://www.wikidata.org/entity/Q36342810

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis.

@ast

Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis.

@en

type

Item

label

Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis.

@ast

Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis.

@en

prefLabel

Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis.

@ast

Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis.

@en

P1476

Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis

@en

P2093

Alan J Worsley

http://www.w3.org/2001/XMLSchema#string

Angel Y S Wong

http://www.w3.org/2001/XMLSchema#string

Ian C K Wong

http://www.w3.org/2001/XMLSchema#string

Shweta Anand

http://www.w3.org/2001/XMLSchema#string

P2860

Azithromycin and the risk of cardiovascular death

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Drug-induced acute myocardial infarction: identifying 'prime suspects' from electronic healthcare records-based surveillance system

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease

Chlamydia pneumonia (and other infective agents) in atherosclerosis and acute coronary syndromes. How good is the evidence?

Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia.

Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study

Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?

Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial

P2888

s40264-017-0533-2

P304

663-677

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1007/S40264-017-0533-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Esther W Chan

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28397186

http://www.w3.org/2001/XMLSchema#string